CVS Health (CVS) stock is spiraling Friday after the pharmacy chain and health benefits provider announced the appointment of a new CEO.
Effective October 17, David Joyner took over as president and CEO of CVS Health, replacing Karen Lynch, who had been in the position since February 2021. Joyner has 37 years of experience in the healthcare and pharmacy benefit management industries, most recently serving as executive vice president of CVS Health and president of CVS Caremark.
"There is no greater honor than to lead a company whose mission and purpose are completely focused on improving health," Joyner said in a statement. "I came back to CVS Health in 2023 because I believed I could give more to the company, and I take this opportunity today for the same reason. I am proud to continue working side by side with our 300,000 colleagues who are building a world of health around every consumer."
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
The news comes less than three weeks after reports surfaced that CVS was conducting a strategic review of its business and had hired bankers to assist in exploring options, including a possible breakup of its retail and insurance units.
CVS Health's preliminary Q3 results fall short
In the press release, CVS also provided preliminary guidance for its third quarter, calling for earnings per share in the range of $1.05 to $1.10.
The forecast falls well below analysts' expectations for third-quarter earnings of $1.70 per share, according to Yahoo Finance.
"In light of continued elevated medical cost pressures in the Health Care Benefits segment, investors should no longer rely on the Company's previous guidance provided on its second-quarter 2024 earnings call on August 7, 2024," CVS added.
Is CVS stock a buy, sell or hold?
CVS Health has had a rough year on the price charts, as well. Shares have fallen more than 26% since the start of 2024, but Wall Street remains bullish on the healthcare stock.
According to S&P Global Market Intelligence, the average analyst target price for CVS is $70.10, representing implied upside of 20% to current levels. Additionally, the consensus recommendation is Buy.
Financial services firm Argus Research is one of those with a Buy rating the large-cap stock and a $75 price target.
The shares trade at an attractive valuation and CVS boasts a healthy 4.2% dividend yield which seems sustainable, wrote Argus Research analyst Christopher Graja in an October 2 note. However, the analyst admitted that he's "disappointed with the recent performance of the Health Care Benefits business" and is "not sure that our Buy recommendation can withstand another guidance cut or a deterioration in credit-quality metrics."
Related content
-
Trump's Immigration Policies and the Price of Home Healthcare: First 100 DaysPresident Trump's immigration policies may wallop your pocketbook if you rely on a home healthcare aide.
-
Stock Market Today: Stocks Extend a Quiet Winning StreakThe S&P 500 Index could actually close April with a monthly gain, which would be an extraordinary sign of market resilience.
-
Stock Market Today: Stocks Extend a Quiet Winning Streak
The S&P 500 Index could actually close April with a monthly gain, which would be an extraordinary sign of market resilience.
-
How Trump's First 100 Days Have Impacted Your PortfolioPresident Trump's first 100 days in office have been busy, with a flurry of executive orders sparking volatility in the stock and bond markets.
-
Is It Still Worth It to Gift Savings Bonds?Kiplinger editor explores if it's still a good idea to get savings bonds as gifts for children, looking at their returns and usability.
-
Don't Veer Off Course at the First Sign of a Squall in the MarketsWhen markets go nuts and investor sentiment drops, you can keep your sanity by trusting in and sticking with your long-term plan.
-
How Business Owners Can Prepare for a Terminal DiagnosisThe most important thing is readiness, whether the owner faces a life-changing diagnosis or an employee does.
-
Advisers, Take Note: How 2025 Social Security Changes May Impact Your ClientsWhat financial advisers might need to know to help their clients navigate Social Security in 2025.
-
Stock Market Today: Have We Seen the Bottom for Stocks?Solid first-quarter earnings suggest fundamentals remain solid, and recent price action is encouraging too.
-
Social Security Is Taxable, But There Are WorkaroundsIf you're strategic about your retirement account withdrawals, you can potentially minimize the taxes you'll pay on your Social Security benefits.
